Optima XPN 系列超高速離心機

Optima XPN 系列超高速離心機是一款性能卓越的超高速離心機。憑藉網路功能和可定製的安全性和追蹤功能,以確保監控流程和合規性,同時 Optima XPN 系列超高速離心機提供全面的安全性能,以實現安全和有效迅速的實驗工作環境。

  • 配備先進的 eXpert 離心專業軟體 
  • 提供 100k,90k 和 80k RPM 轉速配置 
  • 相容多種的轉子類型和實驗室耗材選項
  • 配置超速系統的安全性能,可控制轉子速度以確保實驗安全性

 

產品名稱:超高速離心機 生產企業:貝克曼庫爾特(美國)股份有限公司 Beckman Coulter,Inc.
*僅供醫療衛生專業人士參考
*禁忌內容或者注意事項詳見說明書

 

 

 
 

功能特點

運行前優化實驗方案

使用專有軟體快速執行常見計算和轉換,以優化操作協議,節省寶貴的實驗時間,同時節約樣本。

由電子郵件接收診斷警報

儀器將發送診斷通知給所有用戶的電子郵件帳戶,您也可以使用 VNC(虛擬網路連接從筆記型電腦或其他遠程設備連接儀器)。

 

追蹤詳細使用歷史記錄

安全和追蹤功能通過序列號管理轉子。密碼保護和電子簽名可幫助您維護監控流程和合規性。

操作安全性升級

  • 動態轉子慣性檢查(DRIC)
  • 轉子超速監測
  • 真實和模擬測試
  • 高強度結構鋼腔門帶有螺線管連鎖裝置,可防止操作員與轉動中的轉頭接觸

產品規格明細

BioSafe Yes
Acceleration 10 acceleration profiles
Deceleration 11 deceleration profiles
Speed Control ± 2 rpm of set speed (above 1,000 rpm)
Timed Run 999 hrs, 59 mins (including hold runs)
Max Capacity Volume Range - 1500 mL
Temperature Control ± 0.5 °C of set temperature
Temperature Range(s) Set temperature range: 0 to 40°C in 1°C increments, Ambient temperature range: 10° to 35°C
Display Full-color LCD touch screen
Item Specifications Referenced B10053

Explore Optima XPN Models

Content and Resources

Filter by:
Resource Type
Virus concentration from aqueous solutions by ultracentrifugation Ultracentrifugation is a technique capable of concentrating viruses from aqueous solutions, basically this is done by a simple pelleting step that concentrates the virus from a solution in a small pellet at the bottom of a centrifuge tube
Get Out of the Lab More…Get More Out of the Lab - With Beckman Coulter’s New Instrument Scheduler Software Application In a shared-device environment, you need to know your centrifuge is going to be available when you need it
Beckman Coulter Centrifuges Support 21 CFR Part 11 Compliance Avanti JXN high-performance and Optima XPN ultra centrifuges offer solutions to support 21 CFR Part 11 regulations, making it easy to use our centrifuges and remain compliant
Product Solutions for Viral Research Workflows Brochure: Discover product solutions for sample collection, isolation and preparation, virus identification, antibody analysis, and vaccine and therapy development.

Technical Documents